Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia

T J Kipps1

  • 1Department of Medicine, University of California San Diego, La Jolla 92093-0663, USA.

Current Opinion in Hematology
|September 25, 1998
PubMed
Summary
This summary is machine-generated.

Recent advancements in chronic lymphocytic leukemia (CLL) research offer new insights into its genetic basis, immune system impact, and treatment options. Future therapies may include targeted gene and bone marrow treatments for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Leukemia·2017
Same author

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.

Leukemia·2017
Same author

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.

Leukemia·2017
Same author

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Leukemia·2017
Same author

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.

Leukemia·2016
Same author

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Leukemia·2016
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
  • Understanding CLL cytogenetics, biology, and therapy is crucial for improving patient outcomes.

Purpose of the Study:

  • To review recent progress in CLL research over the past year.
  • To highlight advancements in understanding CLL cytogenetic abnormalities, immune pathophysiology, and therapeutic strategies.

Main Methods:

  • Literature review of recent studies on chronic lymphocytic leukemia.
  • Analysis of findings related to cytogenetics, surface antigens, immune response, and treatment efficacy.

Main Results:

  • Improved understanding of cytogenetic abnormalities and potential new tumor suppressor genes in CLL.

Related Experiment Videos

  • Enhanced knowledge of surface antigens influencing leukemia cell infiltration.
  • Clues to the mechanisms of immunodeficiency in CLL patients.
  • Promising results from combination chemotherapy with purine analogues.
  • Growing consideration of bone marrow and gene therapy for CLL treatment.

    • Conclusions:

    • Recent research has significantly advanced the understanding of CLL biology and genetics.
    • New therapeutic avenues, including targeted therapies and transplantation, are emerging for CLL management.
    • Further research into cytogenetic abnormalities and immune dysfunction holds promise for novel treatment strategies.